Athersys, Inc. Names Ivor Macleod as Chief Financial Officer
January 15, 2020 at 06:00 am
Share
Athersys, Inc. announced the addition of Mr. Ivor Macleod, CPA, MBA, a highly experienced pharmaceutical executive, to the Athersys leadership team. Mr. Macleod has been appointed Chief Financial Officer, effective as of January 31, 2020, to help plan and execute the financial strategy through potential product commercialization. Ms. Laura Campbell, the Company’s Senior Vice President of Finance, will continue to serve as the principal accounting officer. Mr. Macleod has over three decades of global experience across all aspects of the life sciences value chain, from basic research to commercialization, serving in various executive finance and leadership roles within the life sciences industry. Prior to joining Athersys, Mr. Macleod served as Chief Financial Officer and Chief Compliance Officer of Eisai Inc., the U.S. subsidiary of the Japanese company, Eisai Ltd, where he led the overall financial strategy and performance of the company, including several strategic projects to both commercialize and optimize performance of portfolio products.
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells are alternatively obtained from other tissue sources. It is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).